Harnessing the immune system’s full potential to fight human disease.
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Press Releases
18 June 2021
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based ..
10 June 2021
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Go..
28 May 2021
Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 ..
